Outcome of Transarterial Radioembolization in the Treatment of Hepatocellular Carcinoma: Glass Versus Resin Microsphere
- 14 May 2024
- journal article
- research article
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 47 (9) , 1210-1221
Abstract
Purpose To compare the treatment outcomes of glass and resin microspheres for the treatment of hepatocellular carcinoma (HCC) and evaluate the prognostic factors that influence the outcomes. Materials and Methods We retrospectively reviewed 251 consecutive patients who underwent radioembolization for the treatment of HCC at a single tertiary center. Imaging responses after radioembolization were evaluated using the modified Response Evaluation Criteria in Solid Tumors (mRECIST) 1.1. Progression-free survival (PFS) and overall survival (OS) were analyzed using the Kaplan–Meier method. Univariate and multivariate Cox proportional hazard models were used to identify the prognostic factors. Results A total of 195 patients were included in this study (glass microsphere, n = 75; resin microsphere, n = 120). The complete and objective response rates were 16.0% and 50.7% in the glass microsphere group and 17.5% and 58.3% in the resin microsphere group, respectively. Median PFS was 241 days in the glass microsphere group and 268 days in the resin microsphere group (p = 0.871). Median OS was 29 months in the glass microsphere group and 40 months in the resin microsphere group (p = 0.669). The only significant prognostic factor was bilobar tumor distribution, which favored resin microspheres (p = 0.023). Procedure-related adverse events occurred more frequently in the resin microsphere group (glass, 2.7% vs. resin, 5.0%; p < 0.001). Conclusion Glass and resin microspheres for the treatment of HCC did not show a significant difference in survival, though major adverse events occurred more frequently with the use of resin microspheres. Graphical AbstractKeywords
This publication has 26 references indexed in Scilit:
- A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2022
- Yttrium‐90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY StudyHepatology, 2021
- Ablative Transarterial Radioembolization Improves Survival in Patients with HCC and Portal Vein Tumor ThrombusCardioVascular and Interventional Radiology, 2020
- The number of microspheres in Y90 radioembolization directly affects normal tissue radiation exposureEuropean Journal of Nuclear Medicine and Molecular Imaging, 2019
- Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver DiseasesHepatology, 2018
- Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective StudyCardioVascular and Interventional Radiology, 2017
- Cirse Quality Assurance Document and Standards for Classification of Complications: The Cirse Classification SystemCardioVascular and Interventional Radiology, 2017
- Comparison of the Adverse Event Profile of TheraSphere® with SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma: A Systematic ReviewCardioVascular and Interventional Radiology, 2017
- AASLD guidelines for the treatment of hepatocellular carcinomaHepatology, 2017
- Survival after Yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluationHepatology, 2011